PRADA

Preclinical development of alpha-synuclein disaggregating therapeutic peptides for the treatment of Parkinson's disease

 

 

Description

Parkinson's disease is the second most common age-related neurodegenerative disease and an immense burden for patients and healthcare systems. Antibody-based clearing approaches pursued to date have targeted the immune system-assisted degradation of disease-associated alpha-synuclein (αSyn) aggregates, but have not yet achieved a breakthrough in clinical trials. The PRADA consortium of Priavoid GmbH, trenzyme GmbH, NMI and LMU is developing new active substances from the innovative class of all-D peptides, which, due to their unique mode of action, are able to break down existing αSyn aggregates into harmless αSyn monomers. For the first time, they open up possibilities for the curative treatment of Parkinson's disease. The project is developing predictive three-dimensional human cell models and innovative electrophysiological, imaging and AI-based analysis methods for the targeted development and detailed decoding of the mode of action of all-D peptides.

Period:
01.07.2024 - 30.06.2027
FKZ:
16LW0575

Projectlead

Dr. Udo Kraushaar

Group Leader Electrophysiology